Dynamic BH3 Profiling in Lung Cancer

Natalia Díaz Valdivia and Jordi Alcaraz.
Photo Credit: Courtesy of Universitat de Barcelona

Scientific Frontline: Extended "At a Glance" Summary: Dynamic BH3 Profiling in Lung Cancer Therapies

The Core Concept: Dynamic BH3 profiling (DBP) is an advanced functional assay that predicts the efficacy of specific cancer treatments by testing them directly on living tumor cells.

Key Distinction/Mechanism: Unlike genomic sequencing that solely identifies genetic mutations, DBP functionally measures a tumor's apoptotic response (programmed cell death), acting similarly to an antibiogram to determine if targeted therapies will be lethal to the specific cancer cells.

Major Frameworks/Components:

• ALK Inhibitors: Targeted drugs aimed at the 5% of NSCLC patients with alterations in the ALK oncogene; these inhibitors can effectively cross the blood-brain barrier to treat central nervous system metastases.
• Apoptosis Regulation: The critical cellular balance between pro- and anti-apoptotic proteins that dictates whether a tumor cell survives or succumbs to a therapeutic agent.
• BH3 Mimetics: Specialized small molecules that inhibit anti-apoptotic proteins. They are utilized to prevent acute tumor adaptation and overcome cellular resistance to primary treatments.

Antibiotic Limits in Stopping Strep Spread

Ronny Gunnarsson, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg.
 Photo Credit: Pernilla Häyhänen

Scientific Frontline: Extended "At a Glance" Summary: Antibiotic Efficacy in Preventing Invasive Streptococcal Infections

The Core Concept: Prescribing antibiotics for uncomplicated, acute sore throats has a negligible effect on preventing the population-level spread of potentially life-threatening invasive Group A streptococcus (iGAS) infections.

Key Distinction/Mechanism: While antibiotics are routinely debated as a preventive measure against iGAS, the infection's transmission dynamics render this approach highly ineffective. Most patients seek care after their peak contagious window, and up to 25% of iGAS cases are transmitted by asymptomatic carriers who would not trigger clinical intervention.

Major Frameworks/Components:

• Statistical Inefficacy: Even under an extreme theoretical model where every sore throat patient is tested and treated, only 6.7% of iGAS cases in children and 2.8% in adults could be prevented.
• Guideline Limitations: When adhering strictly to targeted diagnostic symptom guidelines (such as the Centor criteria), the maximum preventive effect drops to 1.6% in children and 1.2% in adults.
• Resource Burden: Preventing a single case of iGAS requires conducting between 45,000 and 110,000 throat swabs and dispensing up to 110,000 antibiotic prescriptions, which creates severe strain on primary care infrastructure and elevates the risk of widespread antibiotic side effects.